Sentence examples for development of novel measures from inspiring English sources
It was, therefore, concluded that the development of novel measures to evaluate symptoms and impacts would be of value for both clinical research and clinical practice.
As such, this graph provides a useful summary and a highly visual map of the chemistry reported in the paper -a document summary- and further analyses of this and graphs derived from other papers will open the door to the development of novel measures of document similarity (e.g. in terms of the chemical transformations reported in a corpus of synthesis papers).
Fourth, the implemented MESUR services can be enhanced to support the development of novel measures by allowing users to submit their own rankings which can then automatically be placed in the context of existing measures.
The incorporation of measures of childhood experiences into an adult well-being survey is largely unexplored and consequently this study required the development of novel measures of childhood adversity and happiness.
The new complex of biomedical science-research community-society nowadays compared with situation 60 years ago needs a series of novel measures to exclude errors and balance the further development.
Understanding lipid protein interactions to enhance our knowledge of membrane architecture is a critical step in the development of novel therapeutic measures to respond to the drastic rise of drug resistant microorganisms.
Understanding the molecular mechanisms of A. marginale-tick interactions for R. microplus, one of the most important vectors of A. marginale worldwide, is fundamental toward development of novel control measures [ 22].
These features make GOssTo a practical environment for both the development of novel semantic similarity measures as well as for the calculation of semantic similarities on a genomic scale.
A preference of decision makers for the maximization of commercial headroom made the development of novel methods to measure biomarkers used in primary prevention the most attractive strategy.
It has insisted on the highest standards in accordance with the requirements of international regulatory agencies when evaluating potential therapies, whilst at the same time supporting the development of novel means of measuring the efficacy, pharmacokinetics and pharmacodynamics of the drugs in action.
After the scoring phase it became apparent that the development of novel methods to measure biomarkers that can be used in secondary prevention of DM2 was certainly an unattractive research objective.
